natgillin/translations-raw huggingface dataset:
The compound for use according to claim 12, wherein the RNA viral polymerase is Ebola, yellow fever, Marburg, influenza A, or influenza B viral polymerase. 
Spoj za uporabu sukladno zahtjevu 12, pri čemu je virusna RNK polimeraza virusna polimeraza Ebola virusa, virusa žute groznice, Marburg virusa, virusa influence A ili virusa influence B.
The compound for use according to any one of claims 1-15, wherein the subject is a mammal. 
Spoj za uporabu sukladno bilo kojem od zahtjeva 1-15, pri čemu je subjekat sisavac.
The compound for use according to any one of claims 1-15, wherein the subject is a human. 
Spoj za uporabu sukladno bilo kojem od zahtjeva 1-15, pri čemu je subjekat čovjek.
The compound for use according to any preceding claim, further comprising administration of an additional anti-viral agent, optionally wherein the additional anti-viral agent is laninamivir, oseltamivir, zanamivir, or peramivir. 
Spoj za uporabu sukladno bilo kojem od predhodnih zahtjeva, koje nadalje sadrži davanje dodatnog antivirusnog sredstva, pri čemu je opcijski dodatno antivirusno sredstvo laninamivir, oseltamivir, zanamivir, ili peramivir.
The compound for use according to claim 18, wherein the additional anti-viral agent is peramivir. 
Spoj za uporabu sukladno zahtjevu 18, pri čemu je dodatno antivirusno sredstvo peramivir.
A compound of Formula la: in combination with abiraterone for use in the therapeutic treatment of a hyperproliferative disorder, wherein the hyperproliferative disorder is prostate cancer. 
Spoj, naznačen time, da ima formulu Ia: [image] te se u kombinaciji s abirateronom upotrebljava u terapeutskom postupku liječenja hiperproliferativnog poremećaja, pri čemu se kod hiperproliferativnog poremećaja radi o raku prostate.
The compound in combination for use of claim 1, wherein the compound of formula Ia is for administration sequentially with the abiraterone. 
Spoj u kombinaciji za uporabu prema zahtjevu 1, naznačen time, da je spoj formule Ia namijenjen za uzastopnu primjenu s abirateronom.
The compound in combination for use of claim 1, wherein the compound of formula Ia and the abiraterone, are for administration separately. 
Spoj u kombinaciji za uporabu prema zahtjevu 1, naznačen time, da se spoj formule Ia i abirateron primjenjuju odvojeno.
A compound of formula Ia for therapeutic use in improving the quality of life of a patient treated for prostate cancer with abiraterone. 
[image] te služi za terapeutsku primjenu u svrhu poboljšanja kvalitete života pacijenta koji se liječi od raka prostate pomoću abiraterona.
identifying the sequences for each of said MHC ligand peptides, by fragment spectra clustering and/or database search, 
identificiranje sekvenci za svaki navedeni peptidni ligand MHC, bilo fragmentiranjem klastera i/ili pretraživanjem baze podataka,
determining an average quantity of the MHC ligand peptide by grouping areas between different runs, and normalizing said areas within replicate runs, in order to create an average value for each sample, 
utvrđivanje prosječne količine peptidnog liganda MHC grupiranjem područja između različitih obrada i normalizacijom navedenih područja unutar repliciranih obrada, kako bi se izračunala prosječna količina za svaki uzorak,
label-free quantification of the MHC ligand peptide. 
kvantifikacija peptidnog liganda MHC bez oznake.
The method of claim 1, wherein said method allows handling of tissue samples of different amounts and MHC expression levels. 
Metoda prema zahtjevu 1, gdje navedena metoda dopušta rukovanje uzorcima tkiva različitih količina i razina ekspresije MHC.
The method according to claim 1 or 2, wherein said diseased sample is a tumor sample or a sample of infected tissue. 
Metoda prema zahtjevima 1 ili 2, gdje je navedeni bolesni uzorak uzorak tumora ili uzorak zaraženog tkiva.
The method of any of claims 1 to 4, wherein said method is capable of being performed incrementally by increasing an existing dataset from earlier tested samples with data of new samples. 
Metoda prema bilo kojem zahtjevu od 1 do 4, gdje se navedena metoda može izvesti u koracima s postepenim povećavanjem postojeće grupe podataka iz prethodno testiranih uzoraka s podacima novih uzoraka.
The method of claim 6, wherein the areas are normalized within replicate runs by a method comprising: 
Metoda prema zahtjevu 6, gdje su područja noramalizirana unutar repliciranih obrada metodom koja uključuje:
(f2a) calculating a mean presentation value of each peptide for all samples of a defined preparation antibody; 
(f2a) izračunavanje prosječne prezentacijske vrijednosti svakog peptida za sve uzorke definiranog preparacijskog antitijela;
The method of any of claims 1 to 8, wherein the presentation score is a p-value of a linear mixed model or a p-value of a t-test. 
Metoda prema bilo kojem zahtjevu od 1 do 8, gdje je prezentacijski rezultat veličina p linearnog mješovitog modela ili veličina p t-testa.
The method of claim 9, wherein the presentation score is adjusted for multiple testing using false discovery rate. 
Metoda prema zahtjevu 9, gdje je prezentacijski rezultat prilagođen za višekratno testiranje uporabom lažne stope pronalaženja.
Process for removing H2S from a H2S contaminated energy production gas stream containing methane, using an aqueous biofilter system (10) comprising a biofilter (6) having biofilter support material constituting a biofilter bed supporting a humidified biofilm having microorganisms that are capable of oxidizing H2S, wherein the process comprises the steps of 
Postupak za uklanjanje H2S iz struje plina za proizvodnju energije koja sadržava metan, onečišćene s H2S, korištenjem vodenog biofiltra (10), koji se sastoji od biofiltra (6) s materijalom nosača biofiltra koji čini nosivi sloj biofiltra na koji je postavljen ovlaženi biofilm s mikroorganizmima koji mogu oksidirati H2S, pri čemu postupak obuhvaća korake:
oxidation of at least part of the H2S in the H2S contaminated energy production gas stream by the microorganisms, resulting in a H2S depleted energy production gas stream, CHARACTERIZED IN THAT the process further comprises the step of humidifying the biofilm by means of the energy production gas stream which has been pre-humidified prior to contacting the biofilm, adding an aqueous nitrate solution to the H2S contaminated energy production gas stream by means of an atomizer nozzle adapted to atomize the nutrient and/or nitrate solution into the energy production gas stream, prior to being contacted with the microorganisms, enabling the microorganisms to oxidize the H2S under anoxic conditions, whereby a part of the H2S depleted energy production gas stream is recirculated, wherein the nutrient and/or the nitrate solution is injected to the biofilter together with the recirculated part of the H2S depleted energy production gas stream by using the atomizer nozzle. 
oksidacija barem dijela H2S u struji plina za proizvodnju energije, onečišćene s H2S, pomoću mikroorganizama, što dovodi do potrošnje H2S u struji plina za proizvodnju energije, naznačen time, da postupak nadalje obuhvaća korak vlaženja biofilma pomoću struje plina za proizvodnju energije koja je prethodno ovlažena prije dovođenja u kontakt sa biofilmom, dodavanjem vodene otopine nitrata u struju plina za proizvodnju energije onečišćene s H2S, pomoću mlaznice za raspršivanje prilagođene za raspršivanje otopine hranjivih tvari i / ili otopine nitrata u struju plina za proizvodnju energije, prije dovođenja u kontakt s mikroorganizmima, omogućujući mikroorganizmima da oksidiraju H2S pod anoksičnim uvjetima, pri čemu dio plinovite struje za proizvodnju energije s potrošenim H2S recirkulira, i pri čemu se hranjive tvari i / ili otopina nitrata ubrizgavaju u biofiltar zajedno s recirkuliranim dijelom plinovite struje za proizvodnju energije s potrošenim H2S pomoću mlaznice za raspršivanje.
A process according to claim 1, CHARACTERIZED IN THAT the nitrate solution comprises a chelating agent that is adapted to prevent clogging of inert precipitating agents and other substances formed through the anoxic oxidation of the H2S by the microorganisms. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da otopina nitrata sadržava kelacijsko sredstvo koje je namijenjeno sprečavanju začepljenja sredstvima za taloženje i drugim tvarima koje nastaju anoksičnom oksidacijom H2S pomoću mikroorganizama.
A process according to claim 2, CHARACTERIZED IN THAT for prevention of clogging of calcium sulphate precipitation, the chelating agent comprises ethylene diamine tetra acetic acid (EDTA). 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da za sprečavanje začepljenja taloženjem kalcijevim sulfatom, kelacijsko sredstvo sadržava etilen diamin tetra-octenu kiselinu (EDTA).
A process according to any one of claims 1 to 4, CHARACTERIZED IN THAT the process comprises the step of automatically adjusting the dosage of the nutrient solution added to the H2S contaminated energy production gas stream in relation to the H2S content in the H2S contaminated energy production gas stream at an inlet of the biofilter system (10). 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da obuhvaća korak automatskog podešavanja doze otopine hranjivih tvari dodanih u struju plina za proizvodnju energije koja je onečišćena s H2S u odnosu na sadržaj H2S u struji plina za proizvodnju energije koja je onečišćena s H2S na ulazu biofiltra.
Aqueous biofilter system (10) according to any one of claims 6 to 8, CHARACTERIZED IN THAT the controller (3) is arranged to adapt the dosage of the nitrogen and the phosphor source in the nutrient solution separately. 
Sustav vodenog biofiltra (10) u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačen time, da je upravljački uređaj postavljen tako da prilagodi odvojeno doziranje izvora dušika i izvora fosfora u hranjivoj otopini.
A compound according to claim 4, wherein X is oxygen. 
Spoj sukladno patentnom zahtjevu 4, naznačeno time, da je X kisik.
The compound according to claim 5, wherein the compound is 2-bromo-3,5-dimethoxytrifluoroacetanilide. 
Spoj sukladno patentnom zahtjevu 5, naznačeno time, da je spoj 2-bromo-3,5-dimetoksitrifluoroacetanilid.
The compound according to claim 5, wherein the compound is 2,4-dibromo-3,5-dimethoxytrifluoroacetanilide. 
Spoj sukladno patentnom zahtjevu 5, naznačeno time, da je spoj 2,4-dibromo-3,5-dimetoksitrifluoroacetanilid.
The compound according to claim 5, wherein the compound is 2-cyano-3,5-dimethoxytrifluoroacetanilide. 
Spoj sukladno patentnom zahtjevu 5, naznačeno time, da je spoj 2-cijano-3,5-dimetoksitrifluoroacetanilid.
The compound according to claim 5, wherein the compound is 2-amino-4,6-dimethoxybenzonitrile. 
Spoj sukladno patentnom zahtjevu 5, naznačeno time, da je spoj 2-amino-4,6-dimetoksibenzonitril.
a recombinant antigen receptor, which binds an antigen; and a recombinant co-stimulatory ligand, which is CD80 or 4-1BBL. 
T-stanica koja sadrži: rekombinantni receptor antigena, koji veže antigen; i rekombinantni ko-stimulacijski ligand, koji je CD80 ili 4-1BBL.
a recombinant antigen receptor, which binds an antigen; and a vector encoding a co-stimulatory ligand, which co-stimulatory ligand is CD80 or 4-1BBL. 
T-stanica koja sadrži: rekombinantni receptor antigena, koji veže antigen; i vektor koji kodira ko-stimulacijski ligand, navedeni ko-stimulacijski ligand je CD80 ili 4-1BBL.
The T cell of claim 6 or claim 7, wherein the co-stimulatory ligand is constitutively expressed on the surface of the T cell. 
T-stanica prema zahtjevu 6 ili zahtjevu 7, naznačena time da je ko-stimulacijski ligand konstitutivno eksprimiran na površini T-stanice.
The T cell of any one of claims 1 to 14, wherein the antigen is selected from the group consisting of prostate-specific membrane antigen (PSMA), Carcinoembryonic Antigen (CEA), IL13R alpha, her-2, CD19, NY-ESO-1, HIV-1 Gag, Lewis Y, Mart-1, gp100, tyrosinase, WT-1, hTERT, and mesothelin. 
T-stanica prema bilo kojem od zahtjeva 1 do 14, naznačena time da je antigen odabran iz skupine koju čine membranski antigen specifičan za prostatu (PSMA), karcinoembrijski antigen (CEA), IL13R alfa, her-2, CD19, NY-ESO-1, HIV-1 Gag, Lewis Y, Mart-1, gp100, tirozinaza, WT-1, hTERT, i mezotelin.
The T cell of claim 16, wherein said second recombinant co-stimulatory ligand is selected from the group consisting of OX40L, CD70, LIGHT, CD30L and CD86. 
T-stanica prema zahtjevu 16, naznačena time da je navedeni drugi rekombinantni ko-stimulacijski ligand odabran iz skupine koju čine OX40L, CD70, LIGHT, CD30L i CD86.
The pharmaceutical composition for use in treatment of neoplasia of claim 20, said composition further comprising a cytokine selected from the group consisting of IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, granulocyte macrophage colony stimulating factor, alpha, beta or gamma interferon and erythropoietin. 
Farmaceutski pripravak namijenjen upotrebi u liječenju neoplazije prema zahtjevu 20, te navedeni pripravak nadalje sadrži citokin odabran iz skupine koju čine IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, faktor stimulacije kolonija granulocita i makrofaga, alfa, beta ili gama interferon i eritropoetin.
B is an immunogenic fragment of PilA, at least 95% identical to amino acids 40-149 of any of SEQ ID NO. 
B je imunogeni fragment PilA, najmanje 95% istovjetan aminokiselinama 40-149 iz bilo kojeg od SEQ ID NO.
127 and A is an immunogenic fragment of Protein E selected from the group consisting of SEQ ID NO. 
127, a A je imunogeni fragment Proteina E, koji se bira iz skupine koju čine SEQ ID NO.
The method of claim 1, wherein the virus is selected from the group consisting of rhinovirus, polio, measles, Ebola, Coxsackie, West Nile, yellow fever, Dengue fever, influenza A, influenza B, lassa, lymphocytic choriomeningitis, Junin, Machupo, guanarito, hantavirus, Rift Valley Fever, La Crosse, California encephalitis, Crimean-Congo, Marburg, Japanese Encephalitis, Kyasanur Forest, Eastern equine encephalitis, Western equine encephalitis, severe acute respiratory syndrome (SARS), parainfluenza, Tacaribe, and Pichinde viruses. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu je virusna infekcija odabran iz skupine koja se sastoji od adenovirusa, virusa denga groznice, virusa influence A, virusa influence B, Junin virusa, virusa morbila, parainfluenca virusa, Pichinde virusa, Punta Toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS virusa, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice.
The immunoresponsive cell of claim 1, wherein the nucleic acid is comprised on a vector. 
T-stanica prema zahtjevu 1, naznačena time da se T-stanica je nukleinskom kiselinom koja kodira ko-stimulacijski ligand.
The compound for use according to claim 1, where the viral infection comprises a virus selected from the group consisting of Ebola, West Nile, yellow fever, Dengue fever, influenza A, influenza B, Rift Valley Fever, and Marburg viruses. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu virusna infekcija sadrži virus odabran iz skupine koja se sastoji od virusa iz obitelji orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae.
if the delivery is completed, prompting the user to recover the identification means; 
ako je doprema gotova, upozoravanja korisnika da preuzme sredstvo za identificiranje;ž
Refrigerated display cabinet (1), according to any of the preceding claims, characterised in that the reversible means comprise, at least, a reversible direction impeller associated with corresponding opposing end openings (16) disposed in the display area (2). 
Rashlađena vitrina (1) u skladu s patentnim zahtjevom 1, naznačena time što reverzibilni elementi sadrže u najmanju ruku potisnik reverzibilnog smjera, povezan s odgovarajućim otvorima na suprotnim krajevima (16), koji se nalaze u dijelu za razgledanje (2).
A represents CH; 
A predstavlja CH;
and pharmaceutically acceptable salts, tautomers, stereoisomers thereof. 
te farmaceutski prihvatljive soli, tautomeri i stereoizomeri istog.
is C3-10cycloalkyl, haloC3-10cycloalkyl, N(Ra)2; 4, 5 or 6 membered saturated or partially saturated heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, optionally bridged by a C1-4alkyl group; 5 membered unsaturated heterocycle containing 1, 2, 3 heteroatoms independently selected from N, O and S, but not more than one of which is O or S; 7-13 membered saturated, partially saturated or unsaturated heterocycle containing heteroatoms independently selected from N, O or S; any of which rings being optionally substituted by one or more groups independently chosen from halogen, hydroxy, amino, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy and haloC1-6alkoxy; 
je C3-10cikloalkil, halogenC3-10cikloalkil, N(Ra)2; 4-, 5- ili 6-članski zasićeni ili djelomično zasićeni heterocikl koji sadrži 1, 2 ili 3 heteroatoma zasebno izabranih među N, O ili S, opcionalno povezani sa C1-4alkil grupom; 5-članski nezasićeni heretocikl koji sadrži 1, 2, 3 heteroatoma zasebno izabranih među N, O i S, ali ne da je više od jednog su O ili S; 7- do 13-članski zasićeni, djelomično zasićeni ili nezasićeni heterocikl koji sadrži heteroatome zasebno izabranih među N, O ili S; svaki od prstenova je opcionalno zamjenjiv sa jednom ili više grupa zasebno izabranih među halogen, hidroksi, amino, C1-6alkil, halogenC1-6alkil, C1-6alkoksi i halogenC1-6alkoksi;
The compound according to claim 1 selected from the following list: 
Spoj prema zahtjevu 1 izabran sa slijedeće liste:
and pharmaceutically acceptable salts, tautomers, stereoisomers thereof. 
te farmaceutski prihvatljive soli, tautomeri i stereizomeri istog.
A compound of general formula (IV): wherein: 
Spoj generalne formule (IV): [image] naznačeno time da:
A represents N; 
A predstavlja N;
The compound of general formula (IV) selected from the following list: 
Spoj generalne formule (IV) izabran sa slijedeće liste:
A pharmaceutical composition comprising an effective amount of one or more compounds according to anyone of claim 9 or 10, alone or in combination with other active compounds, and at least one pharmaceutically acceptable excipient for use in the treatment of hemoglobinopathies. 
Farmaceutski spoj koji sadrži učinkovitu količinu jednog ili više spojeva prema zahtjevima 9 ili 10, sam ili u kombinacji s drugim aktivnim sastojcima, i bar jedna farmaceutski prihvatljiva pomoćna tvar za upotrebu u liječenju hemoglobinopatija.
The pharmaceutical composition according to claim 12 or 13 wherein the further active principle is 2,2-dimethylbutyrate, hydroxyurea, decitabine, erythropoietin, trichostatin, valproic acid, or a combination thereof. 
Farmaceutski spoj prema zahtjevu 12 ili 13, naznačeno time da je daljni aktivni princip 2,2-dimetilbutirat, hidroksiurea, decitabin, eritropoietin, trihostatin, valproinska kiselina ili kombinacija istih.
palletisation of the case in the folded condition, wherein the case in the folded condition is appropriately placed on a pallet or similar device. 
paletiranje kutije u preklopljeno stanje, gdje se kutiju u preklopljenu stanju odgovarajuće smjesti na paletu ili sličnu napravu.
Automated case erecting unit according to claim 9, wherein the at least two suction cup are activated by compressed air supply means via second connection means. 
Automatizirana jedinica za gradnju kutija u skladu s patentnim zahtjevom 9, naznačen time što se najmanje dvije vakuumske prianjaljke aktivira dovodom stlačenog zraka znači preko druge spojnice.
Process according to claim 1 or 2, wherein the catalyst is a catalyst comprising a mutant catalytic domain from a β (1,4)-galactosyltransferase, preferably selected from the group consisting of GalT Y289L, GalT Y289N, GalT Y289I, GalT Y289F, GalT Y289M, GalT Y289V, GalT Y289G, GalT Y289I and GalT Y289A. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time što je katalizator katalizator koji sadrži mutantnu katalitičku domenu iz β(1,4)-galaktoziltransferaze, poželjno izabran iz grupe koja se sastoji od GalT Y289L, GalT Y289N, GalT Y289I, GalT Y289F, GalT Y289M, GalT Y289V, GalT Y289G, GalT Y289I i GalT Y289A.
D is a molecule of interest; 
D je molekula od interesa;
Process for the preparation of an Antibody-Drug conjugate, comprising the steps of: 
Postupak za pripremu konjugata antitijela i lijeka, koji sadrži korake:
when said modified antibody is an azide-modified antibody, said linker-conjugate comprises a (hetero)cycloalkynyl group or an alkynyl group, and one or more molecules of interest; or 
kada je navedeno modificirano antitijelo jednako azid-modificiranom antitijelu, navedeni konjugat linkera sadrži (hetero) cikloalkinil grupu ili alkinil grupu, i jednu ili više molekula od interesa; ili
when said modified antibody is an alkyne-modified antibody, said linker-conjugate comprises an azido group, and one or more molecules of interest, wherein a molecule of interest (D) is conjugated to the antibody via a linker (L); wherein said molecule of interest is a substance that is biologically and/or pharmaceutically active. 
kada je navedeno modificirano antitijelo jednako alkin-modificiranom antitijelu, navedeni konjugat linkera sadrži azido grupu, i jednu ili više molekula od interesa, pri čemu je molekula od interesa (D) konjugat antitijela preko linkera (L); pri čemu je navedena molekula od interesa supstanca koja je biološki i/ili farmaceutski aktivna.
A pharmaceutical composition comprising a compound of any one of claims 1-6, or a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da sadržava spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegov stereoizomer ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
System (1) for the execution, traceability, monitoring and control of a method of reducing the bacterial count in a confined environment, comprising: 
Sustav (1) za primjenu, praćenje, nadzor i upravljanje postupkom smanjenja bakterija u zatvorenom prostoru, sadrži:
an environment identification device (2) containing information relating to the confined environment; 
uređaj (2) za identificiranje prostora koji sadrži informaciju koja se odnosi na zatvoreni prostor;
a device (3) for micronizing a decontaminant substance (12) in the air in the form of a dry fog through a diffuser (9), based on the information contained in the environment identification device (2); 
uređaj (3) za mikroniziranje tvari za dekontaminiranje (12) u zraku u obliku suhe magle kroz difuzor (9), bazirano na informacijama sadržanim u uređaju (2) za identificiranje prostora;
System according to Claim 1, wherein the environment identification sensor (2) comprises memory means (7) containing technical information relating to the method for reducing the bacterial count in a confined environment. 
Sustav sukladno patentnom zahtjevu 1, pri čemu senzor (2) za identifikaciju prostora sadrži memorijsku napravu (7) koje sadrži tehničke podatke koji se odnose na metodu za smanjenje broja bakterija u zatvorenom prostoru.
System according to Claim 1 or 2, wherein the micronizing device (3) comprises: 
Sustav sukladno patentnom zahtjevu 1 ili 2, pri čemu uređaj (3) za mikroniziranje sadrži:
a collecting tank (13) adapted to contain the decontaminant substance (12); 
sabirni spremnik (13) prilagođen da sadrži tvar za dekontaminiranje (12);